EUnetHTA develops several services that help inform the decision-making process around the introduction of pharmaceuticals and other technologies at the national, regional and European levels. These include Joint assessments, early diologues and Post Launch Evidence Generation (PLEG)
* Assessment submission: Health technology companies are encouraged to contact us via the following two channels if interested in a EUnetHTA assessment of their product. These are distinguished by EUnetHTA as Pharmaceuticals and Other Technologies (i.e. non-pharmaceuticals).
*Early dialogue: parallel scientific advice with the European Medicines Agency. This aims to allow medicine developers to obtain feedback from regulators and health technology assessment (HTA) bodies on their evidence-generation plans to support decision-making on marketing authorisation and reimbursement of new medicines at the same time.
* Horizon Scanning: topic identificatin, selection and Prioritisation for HTA cooperation